Table 8 Change in other outcomes for 1 year
Outcome | Group | Change from baseline | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|---|
N | Mean | SD | Estimate | 95%CI | P-value | |||
TG (mg/dl) | With atypical antipsychotic | 185 | 5.589 | 130.910 | 8.669 | (−13.141, | 30.478) | 0.435 |
Without atypical antipsychotic | 185 | 5.173 | 103.008 | – | – | – | – | |
HDL-C (mg/dl) | With atypical antipsychotic | 185 | −0.568 | 12.582 | 0.104 | (−2.359, | 2.566) | 0.934 |
Without atypical antipsychotic | 185 | −0.346 | 10.109 | – | – | – | – | |
LDL-C (mg/dl) | With atypical antipsychotic | 185 | 6.130 | 25.689 | 5.537 | (−0.178, | 11.253) | 0.058 |
Without atypical antipsychotic | 185 | 0.454 | 25.469 | – | – | – | – | |
HbA1c (%) | With atypical antipsychotic | 144 | −0.051 | 0.350 | −0.075 | (− 0.159, | 0.008) | 0.075 |
Without atypical antipsychotic | 145 | 0.059 | 0.360 | – | – | – | – | |
Framingham score (LDL) | With atypical antipsychotic | 185 | 0.562 | 2.335 | 0.224 | (−0.246, | 0.693) | 0.349 |
Without atypical antipsychotic | 185 | 0.286 | 1.967 | – | – | – | – | |
JALS score | With atypical antipsychotic | 147 | 2.433 | 8.329 | 1.442 | (−0.435, | 3.319) | 0.132 |
Without atypical antipsychotic | 157 | 1.452 | 7.427 | – | – | – | – | |